Michael Untch
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
01.01.2022Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
01.01.2022JAMA Oncol 2022; 8:1010-1018
Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 2021
17.11.2021Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
17.11.2021Eur J Cancer 2021
Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer 2021; 7:142.
11.11.2021Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
11.11.2021NPJ Breast Cancer 2021; 7:142
Metzger-Filho Otto, von Minckwitz Gunter, Rastogi Priya, Li Lang, Cheng Lijun, Maag David, Wolmark Norman, Denkert Carsten, Symmans W Fraser, Geyer Charles E, Loibl Sibylle, Sikov William M, Golshan Mehra, Collier Katharine, Asad Sarah, Ansell Peter J, Watson Mark, Bae Junu, Cherian Mathew, O'Shaughnessy Joyce, Untch Michael, Rugo Hope S, Huober Jens, Stover Daniel G
Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Paluchowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 2021; 81:e31.
22.10.2021Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
22.10.2021Geburtshilfe Frauenheilkd 2021; 81:e31
Ditsch Nina, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Schmidt Marcus, Schneeweiss Andreas, Thill Marc, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Loibl Sibylle, Kümmel Sherko, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Banys-Paluchowski Maggie, Müller Volkmar, Janni Wolfgang, Kühn Thorsten, Budach Wilfried, Dall Peter, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva M, Friedrich Michael
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Pachulowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 2021; 81:1112-1120.
06.10.2021AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
06.10.2021Geburtshilfe Frauenheilkd 2021; 81:1112-1120
Ditsch Nina, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Schmidt Marcus, Schneeweiss Andreas, Thill Marc, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Loibl Sibylle, Kümmel Sherko, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Banys-Pachulowski Maggie, Müller Volkmar, Janni Wolfgang, Kühn Thorsten, Budach Wilfried, Dall Peter, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva M, Friedrich Michael
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer 2021; 156:138-148.
24.08.2021Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
24.08.2021Eur J Cancer 2021; 156:138-148
Möbus Volker, Reinisch Mattea, Link Theresa, Sinn Bruno V, Janni Wolfgang, Denkert Carsten, Furlanetto Jenny, Engels Knut, Solbach Christine, Schmatloch Sabine, Rey Julia, Burchardi Nicole, Loibl Sibylle, Stickeler Elmar, Huober Jens, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, GBG and AGO-B
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübbe K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22:1151-1161.
09.07.2021Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
09.07.2021Lancet Oncol 2021; 22:1151-1161
Denkert Carsten, Huober Jens, Rhiem Kerstin, Marme Frederik, Reimer Toralf, Schmidt Marcus, Sinn Bruno V, Janni Wolfgang, Stickeler Elmar, Michel Laura, Stötzer Oliver, Hahnen Eric, Furlanetto Jenny, Seiler Sabine, Nekljudova Valentina, Untch Michael, Solbach Christine, Lübbe Kristina, Seither Fenja, Schneeweiss Andreas, Link Theresa, Blohmer Jens-Uwe, Just Marianne, Wimberger Pauline, Forberger Almuth, Tesch Hans, Jackisch Christian, Schmatloch Sabine, Reinisch Mattea, Solomayer Erich F, Schmitt Wolfgang D, Hanusch Claus, Fasching Peter A, Loibl Sibylle
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Marme F, Loibl S, Lederer B, Tesch H, Hanusch C, Denkert C, Rey J, Rhiem K, Link T, Nekljudova V, Jackisch C, Fasching P, Huober J, Blohmer J, Schneeweiss A, Michel L, Solbach C, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 153:203-212.
26.06.2021Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
26.06.2021Eur J Cancer 2021; 153:203-212
Marme Frederik, Loibl Sibylle, Lederer Bianca, Tesch Hans, Hanusch Claus, Denkert Carsten, Rey Julia, Rhiem Kerstin, Link Theresa, Nekljudova Valentina, Jackisch Christian, Fasching Peter A, Huober Jens, Blohmer Jens-Uwe, Schneeweiss Andreas, Michel Laura, Solbach Christine, Untch Michael
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
Thill M, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Jackisch C, Friedrich M, Kolberg-Liedtke C, Fallenberg E, Fasching P, Fehm T, Kümmel S, Kühn T, Krug D, Kreipe H, Huober J, Heil J, Harbeck N, Gluz O, Gerber B, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:214-227.
01.06.2021AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
01.06.2021Breast Care (Basel) 2021; 16:214-227
Thill Marc, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Maass Nicolai, Lux Michael P, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Janni Wolfgang, Müller Volkmar, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Luftner Diana, Loibl Sibylle, Dall Peter, Budach Wilfried, Blohmer Jens-Uwe, Bauerfeind Ingo, Banys-Paluchowski Maggie, Albert Ute-Susann, Jackisch Christian, Friedrich Michael, Kolberg-Liedtke Cornelia, Fallenberg Eva M, Fasching Peter A, Fehm Tanja, Kümmel Sherko, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Gluz Oleg, Gerber Bernd, Ditsch Nina
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
Ditsch N, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Fallenberg E, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Kolberg-Liedtke C, Friedrich M, Fasching P, Fehm T, Gerber B, Kümmel S, Kühn T, Krug D, Kreipe H, Jackisch C, Huober J, Heil J, Harbeck N, Gluz O, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:228-235.
27.05.2021AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
27.05.2021Breast Care (Basel) 2021; 16:228-235
Ditsch Nina, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Maass Nicolai, Lux Michael P, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Janni Wolfgang, Müller Volkmar, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Luftner Diana, Loibl Sibylle, Fallenberg Eva M, Dall Peter, Budach Wilfried, Blohmer Jens-Uwe, Bauerfeind Ingo, Banys-Paluchowski Maggie, Albert Ute-Susann, Kolberg-Liedtke Cornelia, Friedrich Michael, Fasching Peter A, Fehm Tanja, Gerber Bernd, Kümmel Sherko, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Jackisch Christian, Huober Jens, Heil Jörg, Harbeck Nadia, Gluz Oleg, Thill Marc
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
Untch M, Harbeck N, Thill M, Schneeweiss A, Müller V, Luftner D, Loibl S, Kühn T, Krug D, Kolberg-Liedtke C, Janni W, Jackisch C, Huober J, Haidinger R, Denkert C, Budach W, Brucker S, Fasching P, Thomssen C. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. Geburtshilfe Frauenheilkd 2021; 81:637-653.
19.05.2021Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
19.05.2021Geburtshilfe Frauenheilkd 2021; 81:637-653
Untch Michael, Harbeck Nadia, Thill Marc, Schneeweiss Andreas, Müller Volkmar, Luftner Diana, Loibl Sibylle, Kühn Thorsten, Krug David, Kolberg-Liedtke Cornelia, Janni Wolfgang, Jackisch Christian, Huober Jens, Haidinger Renate, Denkert Carsten, Budach Wilfried, Brucker Sara Y, Fasching Peter A, Thomssen Christoph
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:603-608.
01.04.2021Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
01.04.2021JAMA Oncol 2021; 7:603-608
Filho Otto Metzger, Rugo Hope S, Huober Jens, Golshan Mehra, Sikov William M, von Minckwitz Gunter, Rastogi Priya, Maag David, Wolmark Norman, Denkert Carsten, Untch Michael, O'Shaughnessy Joyce, Stover Daniel G, Asad Sarah, Ansell Peter J, Watson Mark, Loibl Sibylle, Geyer Charles E, Bae Junu, Collier Katharine, Cherian Mathew, Symmans W Fraser
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148:159-170.
18.03.2021Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
18.03.2021Eur J Cancer 2021; 148:159-170
Villegas Sonia L, Huober Jens, Lederer Bianca, van Mackelenbergh Marion, Tesch Hans, Jackisch Christian, Rezai Mahdi, Sinn Peter, Sinn Bruno V, Hackmann John, Kiechle Marion, Schneeweiss Andreas, Weichert Wilko, Denkert Carsten, Schmitt Wolfgang D, Hanusch Claus, Nekljudova Valentina, Pfarr Nicole, Engel Jutta, Untch Michael, Schrodi Simone, Holms Frank, Ulmer Hans U, Fasching Peter A, Weber Karsten E, Albig Christian, Heinrichs Clemens, Marme Frederik, Hartmann Arndt, Loibl Sibylle
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy
Furlanetto J, Lederer B, Gerber B, Zahm D, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Couch F, Schmutzler R, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J, Lübbe K, Untch M, Salat C, Huober J, Klare P, Fasching P. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 145:44-52.
07.01.2021Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy
07.01.2021Eur J Cancer 2021; 145:44-52
Furlanetto Jenny, Lederer Bianca, Gerber Bernd, Zahm Dirk-Michael, Bauerfeind Ingo, Nekljudova Valentina, Hanusch Claus, Jackisch Christian, Link Theresa, Hahnen Eric, Loibl Sibylle, Couch Fergus J, Schmutzler Rita, Möbus Volker, Schneeweiss Andreas, Rhiem Kerstin, Tesch Hans, Blohmer Jens-Uwe, Lübbe Kristina, Untch Michael, Salat Christoph, Huober Jens, Klare Peter, Fasching Peter A
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast 2021; 55:138-139.
05.01.2021Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
05.01.2021Breast 2021; 55:138-139
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Huebner H, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Müller V, Wallwiener M, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC cancer 2020; 20:1091.
11.11.2020Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
11.11.2020BMC cancer 2020; 20:1091
Huebner Hanna, Beckmann Matthias W, Belleville Erik, Ruebner Matthias, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Müller Volkmar, Wallwiener Markus, Kurbacher Christian M, Kuesters Geoffrey, Hartkopf Andreas D, Lux Michael P, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Ettl Johannes
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020; 12
17.10.2020Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
17.10.2020Cancers (Basel) 2020; 12
Michel Laura L, Hielscher Carsten, Mundhenke Christoph, Kurbacher Christian, Wuerstlein Rachel, Untch Michael, Overkamp Friedrich, Huober Jens, Janni Wolfgang, Taran Florin-Andrei, Lux Michael P, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Wimberger Pauline, Huebner Hanna, Hartkopf Andreas D, Fasching Peter A, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Volz Bernhard, Fehm Tanja N
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54:88-95.
29.08.2020Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
29.08.2020Breast 2020; 54:88-95
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020
Thill M, Mundhenke C, Moebus V, Maass N, Lux M, Luftner D, Loibl S, Kümmel S, Kühn T, Kreipe H, Park-Simon T, Reimer T, Rhiem K, Wöckel A, Witzel I, Thomssen C, Stickeler E, Solomayer E, Solbach C, Schneeweiss A, Schmidt M, Rody A, Huober J, Heil J, Banys-Paluchowski M, Albert U, Müller V, Janni W, Friedrich M, Krug D, Jackisch C, Kolberg-Liedtke C, Untch M, Bauerfeind I, Blohmer J, Budach W, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Diel I, Dall P, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care (Basel) 2020; 15:294-309.
10.06.2020AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020
10.06.2020Breast Care (Basel) 2020; 15:294-309
Thill Marc, Mundhenke Christoph, Moebus Volker, Maass Nicolai, Lux Michael, Luftner Diana, Loibl Sibylle, Kümmel Sherko, Kühn Thorsten, Kreipe Hans H, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Wöckel Achim, Witzel Isabell, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Chistine, Schneeweiss Andreas, Schmidt Marcus, Rody Achim, Huober Jens, Heil Jörg, Banys-Paluchowski Malgorzata, Albert Ute-Susann, Müller Volkmar, Janni Wolfgang, Friedrich Michael, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Untch Michael, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva Maria, Diel Ingo, Dall Peter, Ditsch Nina
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
Werutsky G, Nekljudova V, Vladimirova V, Kühn T, Rhiem K, Huober J, Krug D, Link T, Schneeweiss A, Gerber B, Jackisch C, Tesch H, Denkert C, Seiler S, Blohmer J, Fasching P, Hanusch C, Untch M, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer 2020; 130:92-101.
13.03.2020Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
13.03.2020Eur J Cancer 2020; 130:92-101
Werutsky Gustavo, Nekljudova Valentina, Vladimirova Valentina, Kühn Thorsten, Rhiem Kerstin, Huober Jens, Krug David, Link Theresa, Schneeweiss Andreas, Gerber Bernd, Jackisch Christian, Tesch Hans, Denkert Carsten, Seiler Sabine, Blohmer Jens-Uwe, Fasching Peter A, Hanusch Claus, Untch Michael, Loibl Sibylle